Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax SA (ABVX)
Company Research
Source: GlobeNewswire
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025. The Universal Registration D
Read more
Impact Snapshot
Event Time:
ABVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABVX alerts
High impacting Abivax SA news events
Weekly update
A roundup of the hottest topics
ABVX
News
- Abivax Announces Full Year 2024 Financial ResultsGlobeNewswire
- ABIVAX Société Anonyme (NASDAQ: ABVX) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $12.00 price target on the stock.MarketBeat
- Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025GlobeNewswire
- Abivax Publishes 2025 Financial CalendarGlobeNewswire
- Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual CongressGlobeNewswire